FDA authorizes emergency use of new SARS-CoV-2 diagnostic tests
The Food and Drug Administration authorized the University of California San Francisco’s Clinical Labs at China Basin to use a new molecular-based diagnostic test for SARS-CoV-2.
The agency also authorized laboratories certified to perform high complexity tests under the Clinical Laboratory Improvement Amendments to use a new molecular-based diagnostic test developed by BioSewoom Inc.
Related News Articles
Headline
The Department of Health and Human Services Dec. 10 amended the Public Readiness and Emergency Preparedness Act declaration for COVID-19, extending liability…
Headline
AHA's latest social media toolkit for encouraging vaccination against the flu and COVID-19 provides fall-themed social media posts and graphics. Download the…
Headline
The Centers for Disease Control and Prevention last week endorsed a recommendation for people aged 65 and older and for immunocompromised individuals to…
Headline
The Centers for Medicare & Medicaid Services Oct. 22 released final guidance detailing reporting requirements for the hospital respiratory data condition…
Headline
The Centers for Disease Control and Prevention is reminding clinicians and other health care workers to take necessary steps to keep themselves and their…
Headline
The National Institutes of Health Oct. 10 released results of a study that found that infection from COVID-19 in the first wave of the pandemic appeared to…